What is the rationale for adding the senolytic drugs dasatinib and quercetin to cilta-cel in the Phase II DART trial?
Myeloma cells from patients who relapse early after CAR T-cell therapy show a senescent-like signature, and senolytics may resensitize these dormant cells to T-cell killing
Dasatinib and quercetin enhance CAR T-cell expansion by inhibiting regulatory T-cells
Senolytics reduce the risk of CRS and delayed neurotoxicity after CAR T-cell infusion